Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Hua Medicine ( (HK:2552) ).
Hua Medicine has announced the successful dosing of the first patient in a U.S.-based Phase Ib trial for their second-generation glucokinase activator, HMS1005. This trial aims to assess the safety and efficacy of the drug, which is designed for once-daily administration to improve GLP-1 secretion in Type 2 diabetes patients. The company plans to seek global partners for further development upon successful completion of this trial, potentially enhancing its market position in diabetes treatment.
The most recent analyst rating on (HK:2552) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on Hua Medicine stock, see the HK:2552 Stock Forecast page.
More about Hua Medicine
Hua Medicine is a pharmaceutical company focused on developing innovative therapies for diabetes. The company is involved in creating glucokinase activators, with a focus on addressing Type 2 diabetes mellitus.
Average Trading Volume: 4,617,321
Technical Sentiment Signal: Buy
Current Market Cap: HK$3.17B
See more data about 2552 stock on TipRanks’ Stock Analysis page.